Rationale for Inhibiting TGFB in Cancer
Although TGFh was originally reported as an oncogene (12) , early studies also showed that it is a potent inhibitor of epithelial cell proliferation (13) . Mice with targeted disruption of TGFb1 and Smad genes as well as transgenic mice with tissuespecific expression of dominant-negative ThRII are prone to cancer development (reviewed in ref. 14) . Inactivating mutations in the TGFBR2 gene occur in both sporadic and inherited colon cancers with microsatellite instability (15) ; restoration of ThRII by transfection reverses transformation in certain colon cancer cell lines (16) . Inactivating mutations in Smad2 and Smad4 are present in cancers of the gastrointestinal tract and pancreas (17) . More recently, conditional inactivation of ThRII in mouse fibroblasts resulted in prostatic intraepithelial neoplasias and carcinomas of the forestomach (18) . These data are consistent with the ability of TGFh to maintain tissue architecture, inhibit genomic instability, and induce replicative senescence and apoptosis in nontransformed cells/tissues (14) . Despite this evidence supporting a tumor suppressor role for TGFh, exogenous TGFh has never been shown to inhibit an established cancer in vivo nor has the administration of a TGFh inhibitor resulted in spontaneous tumor development or the acceleration of an already established cancer in an animal model or in humans.
On the other hand, an excess production and/or activation of TGFh by established tumor cells can promote cancer progression by mechanisms such as an increase in tumor neoangiogenesis and extracellular matrix production, up-regulation of peritumor proteases, and inhibition of immune surveillance mechanisms in the cancer host among others (reviewed in ref. 19 ). High TGFh levels in tumors or in patients' serum correlate with markers of a more metastatic phenotype and/or poor patient outcome (20 -23) . TGFh can also induce an epithelial-to-mesenchymal transition and increase tumor cell invasiveness (24, 25). Re-expression of ThRII in colon cancer cells with low invasive potential restores tumor cells invasiveness (26). Forced expression of dominant-active Smad2 in squamous cancer cells results in enhanced tumor cell motility and metastatic dissemination (27). Finally, expression of dominant-negative ThRII in metastatic cancer cells prevents epithelial-to-mesenchymal transition and inhibits motility, tumorigenicity, and metastases (reviewed in ref. 19) .
There is also evidence that the tumor suppressor versus oncogenic effects of TGFh are contextual and/or depend on the temporal stage of cellular transformation. For example, the expression of a kinase-intact type I receptor (ThRI) mutant that is unable to bind Smad2/3 results in larger, more proliferative, less differentiated mammary tumors. However, expression of the same mutant in highly malignant mammary cells suppresses their ability to metastasize to the lungs (28). In a second example, transgenic mice engineered to lack ThRII in the mammary gland developed Polyomavirus middle T (PyVmT) oncogene-induced mammary tumors with shorter latency and with more lung metastases compared with ThRII-expressing tumors (29). In these mice, the floxed ThRII allele was excised upon crossbreeding with mouse mammary tumor virus (MMTV)/Cre mice, where Cre is expressed in the mammary gland at puberty before mammary tumors are established. This report seems to contrast with another study of triple transgenic (MMTV/rtTA Â tet-op/TGFh1 S223/225 Â MMTV/PyVmT) mice in which active TGFh1 expression at tumor sites was controlled with doxycycline. In their study, 2 weeks of administration of doxycycline to 8-week-old mice with established mammary tumors markedly accelerated metastases and death (30). These data suggest that the net effect of TGFh signaling in tumor progression may diverge as a function of the (early versus late) stage of transformation.
Additional examples support a promoter role for autocrine/ paracrine TGFh in late phases of transformation. Mice overexpressing active TGFh1 in suprabasal keratinocytes develop fewer benign papillomas than controls. However, the few transgenic tumors which do develop acquire a spindle cell phenotype, overexpress TGFh3, and metastasize (31). Overexpression of an active mutant of ThRI (Alk5) or active TGFh1 in the mammary gland of transgenic mice accelerates metastases from Neu-induced mammary tumors (32 -34). Finally, expression of ThRII in tumors has been associated with shorter patient survival in several tumor types (35 -37), suggesting that TGFh signaling in cancer cells may select tumors with high metastatic behavior. Recent reviews have summarized a number of studies in which the inhibition of TGFh by pharmacologic or genetic means inhibited tumor progression in animal models (19, 38, 39) .
TGFB and Oncogenic Signaling Pathways
Recent studies have identified oncogenic signaling pathways which are activated by TGFh. For example, secreted TGFh2 induces nuclear factor nB activity in cancer cells and RNA interference of TGFh2 in LNCaP cells reduces nuclear factor nB activity and survival (40). TGFh stimulates PI3K and Akt activities. Both ThRII and Alk5 associate with p85, the regulatory subunit of PI3K, and expression of constitutively active Alk5
T204D markedly up-regulates PI3K catalytic activity (34, 41, 42). TGFh-or active Alk5-mediated cell motility and protection from apoptosis are blocked by LY294002 (30, 43), dominant-negative Akt (44), dominant-negative c-Jun (45), or ThRI kinase inhibitors (34). Inhibition of PI3K has also been shown to reverse the fibroblastoid phenotype of Ras-transformed hepatocytes to an epithelial phenotype (46), further suggesting that PI3K signaling is an effector of the oncogenic function of TGFh. Transgenic mice expressing an active mutant of Alk5 in the mammary gland exhibit increased PI3K activity in mammary epithelium as well as reduced apoptosis in terminal end buds and during (delayed) postlactational involution (34). Although MMTV/Alk5 T204D mice did not develop mammary tumors, bigenic MMTV/Neu Â Alk5 T204D mice developed cancers that were markedly more metastatic than those occurring in MMTV/Neu mice (34).
Oncogenic signaling pathways activated by TGFh can subvert Smad signaling and, thus, antagonize ligand-induced antiproliferative action. For example, PI3K/Akt represses the induction of p21 CIP1 and, in doing so, inhibits the cytostatic action of TGFh (47). Activated Akt can sequester Smad3 and prevent its phosphorylation, association with Smad4, and nuclear translocation, hence blocking TGFh-induced apoptosis (48, 49). These data may explain in part how oncogenes attenuate the tumor suppressive action of TGFh. How essential these nonSmad oncogenic pathways are for the effects of TGFh on tumor progression remains to be determined.
TGFh cooperates with activated Ras on the conversion of noninvasive to metastatic tumors and on the promotion of epithelial-to-mesenchymal transition (27, 50). Oncogenically activated Ras has been shown to inhibit TGFh-mediated nuclear accumulation of Smad2/3, Smad-dependent transcription, and antimitogenesis (51). Ha-Ras abrogates TGFh-mediated inhibition of proliferation by inducing MAPK-dependent proteasomal degradation of Smad4 (52). TGFh can activate Ras/MAPK signaling in transformed cells (53) and expression of a dominant-negative truncated Alk5 blocks the growth of Rastransformed Jnk À/À tumors in mice (54) , suggesting that autocrine TGFh is at least in part required for Ras-induced transformation in vivo.
TGFh synergizes with other oncogenes that activate Ras/ MAPK. For example, overexpression of active TGFh1 or active Alk5 mutants in the mammary gland of bitransgenic mice also expressing neu/erbB2 accelerates metastases from oncogeneinduced mammary cancers (32 -34). A genetic modifier screen in nontumorigenic mammary epithelial cells identified TGFh1 and TGFh3 as molecules that cooperate with ErbB2 on inducing cell motility and invasion, which were blocked by inhibitors of MAPK (55) . Inhibition of ErbB2 (HER2) with the HER2 neutralizing antibody trastuzumab or with MAPK inhibitors blocked the promigratory effect of TGFh in HER2-overexpressing mammary epithelial cells (56) , suggesting that oncogene function is required for TGFh action. These data imply that (a) oncogenes that activate Ras/MAPK signaling engage and require TGFh for tumor progression, and (b) tumors with activating Ras mutations or with active Ras/MAPK are attractive targets for the testing of TGFh inhibitors.
Therapeutic Inhibitors of TGFB Signaling
The main strategies for inhibition of TGFh include compounds that interfere with the binding of ligand to TGFh receptors, drugs that block intracellular signaling, and antisense oligonucleotides. These have been summarized in recent reviews (38, 39) and will be only mentioned in brief here. Lerdelimumab (CAT-152) and metelimumab (CAT-192) are recombinant human IgGs generated by phage display technology that blocks TGFh1 and h2, respectively (57, 58). They are under development by Cambridge Antibody Technology (London, United Kingdom) and Genzyme Corporation (Framingham, MA). Because of the expression of multiple TGFh isoforms in tumors, a panspecific monoclonal antibody GC-1008 (also developed by CAT/Genzyme) is in early phase I testing in patients with cancer. The phase I studies of CAT-152 and GC-1008 have been conducted in patients with fibrotic disorders, however, the final reports for these are not yet available. In two studies, CAT-152 seemed to prevent subconjunctival scarring after glaucoma filtration surgery (57, 59) . Recombinant fusion proteins containing the ectodomains of the type II and type III (betaglycan) receptors have also been used to prevent ligand binding to TGFh receptors. Soluble ThRII/Fc has shown potent antimetastatic activity in transgenic mice (60) but its clinical development in cancer is unclear at this time. Human recombinant ThRIII has also shown antimetastatic and antiendothelial cell activity (61) in preclinical models.
A second group of strategies is aimed at directly blocking the catalytic activity of ThRI. These include the small molecules SB-431542 and SB-505124 (GlaxoSmithKline, Collegeville, PA), SD-093 and SD-908 (Scios Inc., Fremont, CA), and LY2157299 (Lilly Research Laboratories, Indianapolis, IN), which are ATPcompetitive inhibitors of the Alk5 kinase and whose structural properties have been reviewed recently (39). One difference (and potential advantage) of these compounds from the pharmacologically more stable ligand-specific antibodies is that they cross-react with other Alk5-homologous serine/ threonine kinases such as Alk4 and Alk7, suggesting that they could modulate the activin-mediated activation of Smad2/3 (62 -64) . At the time of this writing, some of these compounds are just entering phase I investigation.
Finally, TGFh antisense approaches are also in development in cancer. In preclinical studies using intracranial gliomas, a TGFh2 antisense-modified allogeneic tumor cell vaccine was shown to inhibit TGFh-mediated immune suppression and promote tumor rejection (65) . Antisense Pharma (Regensburg, Germany) is developing two TGFh-specific phosphorothioate antisense oligonucleotides. AP-12009, against TGFh2, has shown remarkable early clinical activity when delivered intratumorally by convectionenhanced delivery to patients with high-grade gliomas (66) . AP-11014, against TGFh1, is being developed for the treatment of non-small cell, colorectal, and prostate carcinomas (67) .
At this point, therapeutic targeting of TGFh signaling in human cancers has been endorsed by the scientific community.
However, many questions remain about this enterprise as it applies to drug tolerability and/or toxicities, molecular and/or biochemical surrogate markers of TGFh activation and druginduced inactivation in situ, the molecular profile and/or tumor types most appropriate for investigational trials with TGFh inhibitors, and scientifically based combinations that will include inhibitors of TGFh signaling, among others. 
